Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. by Salaverria Frigola, Itziar et al.
Specific Secondary Genetic Alterations in Mantle Cell
Lymphoma Provide Prognostic Information Independent
of the Gene Expression–Based Proliferation Signature
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A B S T R A C T
Purpose
To compare the genetic relationship between cyclin D1–positive and cyclin D1–negative mantle
cell lymphomas (MCLs) and to determine whether specific genetic alterations may add prognostic
information to survival prediction based on the proliferation signature of MCLs.
Patients and Methods
Seventy-one cyclin D1–positive and six cyclin D1–negative MCLs previously characterized by gene
expression profiling were examined by comparative genomic hybridization (CGH).
Results
Cyclin D1–negative MCLs were genetically characterized by gains of 3q, 8q, and 15q, and losses
of 1p, 8p23-pter, 9p21-pter, 11q21-q23, and 13q that were also the most common alterations in
conventional MCLs. Parallel analysis of CGH aberrations and locus-specific gene expression
profiles in cyclin D1–positive patients showed that chromosomal imbalances had a substantial
impact on the expression levels of the genes located in the altered regions. The analysis of
prognostic factors revealed that the proliferation signature, the number of chromosomal aberra-
tions, gains of 3q, and losses of 8p, 9p, and 9q predicted survival of MCL patients. A multivariate
analysis showed that the gene expression-based proliferation signature was the strongest
predictor for shorter survival. However, 3q gains and 9q losses provided prognostic information
that was independent of the proliferative activity.
Conclusion
Cyclin D1–positive and –negative MCLs share the same secondary genetic aberrations, supporting
the concept that they correspond to the same genetic entity. The integration of genetic
information on chromosome 3q and 9q alterations into a proliferation signature-based model may
improve the ability to predict survival in patients with MCL.
J Clin Oncol 25:1216-1222. © 2007 by American Society of Clinical Oncology
INTRODUCTION
Mantle cell lymphoma (MCL) is an aggressive
B-cell non-Hodgkin’s lymphoma that makes up
5% to 10% of all human B-cell lymphomas.1 MCL
is genetically characterized by the chromosomal
translocation t(11;14)(q13;q32)m resulting in
juxtaposition of the cyclin D1 gene and the im-
munoglobulin heavy chain enhancer, leading to
constitutive overexpression of cyclin D1.2 In ad-
dition to cyclin D1 deregulation, secondary chro-
mosomal alterations also play a pivotal role in
MCL lymphomagenesis (eg, by disturbing the
highly coordinated cell cycle regulation or the
response to DNA damage).3 Various studies us-
ing conventional cytogenetics,4,5 comparative
genomic hybridization (CGH),6-10 and array-
based CGH11-13 have revealed a high number of
such secondary chromosomal alterations in MCL,
including gains in 3q, 6p, 7p, 8q, 10p, 12q, and
18q as well as losses of 1p, 6q, 8p, 9p, 9q, 11q, and
13q. Crucial target genes such as p16INK4a in
9p21,14,15 BMI-1 in 10p12,16 ATM in 11q22.3,17-19
CDK4 in 12q14,20 and p53 in 17p1321,22 have been
identified. In addition, alterations in a number of
chromosomal regions show a clear association
with the clinical course of MCL patients.7,10,11,23
In contrast to cyclin D1–positive MCL, data on
genetic alterations in the recently defined small
subgroup of cyclin D1–negative MCL is lacking.24
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No. G03/10), Red temática limfomas (Grant
No. G03/179; to E.C.); the European Union
Contract No. LSHC-CT 2004-503351, the
Interdisciplinary Center for Clinical
Research of the University of Würzburg,
Germany (to A.R.); The Lymphoma
Research Foundation, and by a Director’s
Challenge grant (Grant No. UO1-CA84967)
from the National Cancer Institute,
Bethesda, MD (to W.C.C.).
Presented as oral communication at the
2006 United States and Canadian Academy
of Pathology Annual Meeting, February
11-17, 2006, Atlanta, GA.
I.S., A.Z., and S.B. contributed equally to
this work. A.R. and E.C. are the co-senior
authors of this work.
Authors’ disclosures of potential conflicts
of interest and author contributions are
found at the end of this article.
Address reprint requests to Elias Campo,
MD, Hematopathology Section, Hospital
Clinic, Villarroel 170, 08036-Barcelona,
Barcelona, Spain; e-mail: ecampo@
clinic.ub.es.




JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 25  NUMBER 10  APRIL 1 2007
1216
Downloaded from ascopubs.org by 161.116.168.80 on November 12, 2018 from 161.116.168.080
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Recently, the Leukemia and Lymphoma Molecular Profiling
Project conducted a comprehensive gene expression profiling study of
MCL specimens and identified the proliferation signature as a biologic
integrator of various oncogenic events and as a powerful predictor of
survival, allowing the definition of prognostic subgroups that differ in
median survival by more than 5 years.25 However, the correlation
between the gene expression–based measurement of tumor cell pro-
liferation (proliferation signature) and underlying secondary genetic
alterations in MCL has not yet been elucidated. Secondary chromo-
somal alterations may deregulate a large number of genes that influ-
ence the biologic behavior of the tumor. In a previous study in
diffuse large B-cell lymphoma, we demonstrated that chromo-
somal aberrations had a substantial impact on the expression pro-
file of locus-specific genes and improved the predictive value of the
gene expression– based prognostic model.26 In the present study,
we performed CGH analysis in 77 primary MCL patient samples
(71 cyclin D1–positive and six cyclin D1–negative cases) that were
studied previously by gene expression profiling25 to address three
specific questions. First, we investigated whether the global profile
of genetic alterations in cyclin D1–negative MCL24 is similar to
conventional MCL overexpressing cyclin D1. Second, we exam-
ined the influence of individual chromosomal aberrations on spe-
cific gene expression changes. Finally, we evaluated whether
specific secondary genetic alterations may provide prognostic in-
formation independent from the proliferation signature and,
therefore, improve the predicted survival of MCL patients.
PATIENTS AND METHODS
Patient Characteristics
We studied 77 untreated MCL patients who had been characterized
previously by gene expression profiling using the Lymphochip cDNA micro-
array (National Institutes of Health, Bethesda, MD).25 The analysis of genetic
alterations of these patients has not been published previously. Tumors were
selected for the study on the sole basis of availability of genomic DNA obtained
simultaneously with mRNA extraction from the same frozen tissue used for
gene expression profiling. Seventy-one tumors were classified as cyclin D1–
positive MCL (58 classical and 13 blastoid variants) and six tumors were
classified as cyclin D1–negative MCL. Cyclin D1–positive samples had been
analyzed previously by real-time quantitative polymerase chain reaction
(qPCR) for losses of the p16INK4a, ATM, and p53 gene loci.25 The proliferation
signature of all samples was calculated using the expression levels of 20
proliferation-associated genes.25 Thus, the proliferation signature was built as
a continuous variable, ranging from 1.31 to 1.5. Patients with a proliferation
signature below the median (0.04) were considered as the low proliferation
group, whereas those with the index above the median were considered as the
high proliferation group.
Clinical data were obtained from all patients according to a protocol
approved by the National Cancer Institute Institutional Review Board.
CGH
CGH was performed using a commercially available CGH kit provided
by Vysis (Downers Grove, IL). Hybridizations and digital image acquisition,
processing, and evaluation were performed on a Cytovision Ultra Workstation
(Applied Imaging, Sunderland, United Kingdom) as described previously.7
Signal ratios greater than 1.25 or less than 0.75 were considered as chromo-
somal gains or losses, respectively. Ratios exceeding 1.5 and/or strong focal
signals with the ratio profile showing over-representation were considered as
high-level DNA amplifications. Complete CGH data are available at http://
www.ncbi.nlm.nih.gov/sky.
Statistical Analysis
The association between losses of 9p, 11q, and 17p as detected by CGH
and losses of the p16INK4a, ATM, and p53 loci analyzed by qPCR25 was evalu-
ated using 2 or Fisher’s exact test. In addition, odds ratios (ORs) and 95% CI
were calculated. Kendall’s b (Kt) test was used to assess concordance. To
determine the relationship between chromosomal imbalances and the expres-
sion levels (as a continuous variable) of the genes located in the corresponding
altered chromosomal region (gain versus normal copy number and loss versus
normal copy number), the nonparametric Mann-Whitney test was per-
formed. The association between 3q amplification versus gain versus normal
and the expression levels of the genes in this region was analyzed by means of
the Kruskal-Wallis test. Overall survival was estimated using the Kaplan-Meier
method. Cox proportional hazards models were used to estimate hazard ratios
(HRs) and calculate 95% CIs. Once a chromosomal abnormality was found to
be significant univariately, a likelihood ratio test was used to determine
whether this variable added significantly to the survival model based on the
proliferation signature.25 When multiple chromosomal alterations or genes
were considered in the same analysis, the P values were adjusted for multiple
comparisons using the false discovery rate method,27 as implemented in the R
package multitest version 1.10.2 (http://cran.r-project.org). Adjusted P values
less than .05 were considered significant.
RESULTS
Cyclin D1–Positive and Cyclin D1–Negative MCL Share
Recurrent Chromosomal Alterations
Clinical characteristics of MCL patients are summarized in Table
1. The median age of the patients was 62 years (range, 38 to 92 years),
the ratio of males to females was 58 to 19. Seventy-one patients re-
ceived multiagent chemotherapy, including rituximab in 10 patients;
four patients were not treated, and no information on the treatment
was available in two patients. Overall, the clinical characteristics of the
cyclin D1–positive and cyclin D1–negative patients were similar (Ta-
ble 1). All cyclin D1–negative MCLs had a typical morphology. In
addition, the gene expression–based proliferation signature of the
cyclin D1–positive and cyclin D1–negative tumors showed no statis-
tically significant difference between these two groups (P  .46).
Among the 71 cyclin D1–positive MCLs, 64 (90%) showed
aberrant profiles by CGH analysis, whereas no chromosomal imbal-
ances were detected in seven cases. Among aberrant cases, a total of
86 gains and 184 losses of chromosomal material were observed.
Recurrent chromosomal alterations in cyclin D1–positive and cyclin
D1–negative MCLs are listed in Table 2. In cyclin D1–positive tumors,
chromosomal alterations occur most frequently in 3q, 1p, 13q,
and 11q21-q23 (Fig 1A). No recurrent high-level DNA amplifica-
tions were detected. MCL patients with blastoid morphology
(13%) showed more frequently losses of 9p21-pter than classical
MCL variants (54% v 10%; P  .001). Overall, the global profile of
genomic imbalances detected in our study is well in accordance
with published data.6,7,11,13
In cyclin D1–negative MCL, the most common chromosomal
alterations also affected 3q, 13q, and 11q (Table 2; Fig 1B). Although
the number of cyclin D1–negative patients is small, these results sug-
gest that these two MCL variants share the same profile of secondary
genomic aberrations.
The CGH data in the chromosomal regions 9p21-pter, 11q22-
q23, and 17p were in good concordance with deletions of specific
target genes as detected by qPCR.25 Specifically, losses of 9p21-pter
were significantly associated with deletions of the p16INK4a locus (Kt,
0.67; OR, 43.0; 95% CI, 7.2 to 484.6). Similarly, 11q22-q23 losses were
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associated with deletions of the ATM locus by qPCR (Kt, 0.55; OR,
13.3; 95% CI, 3.5 to 60.0), and losses of 17p13 with p53 gene deletions
(Kt, 0.49; OR, 21.7; 95% CI, 2.5 to 295.8).
Chromosomal Alterations Influence Locus-Specific
Gene Expression
To determine the influence of chromosomal imbalances on
locus-specific gene expression in cyclin D1–positive patients, the ex-
pression level of genes located in seven frequently altered regions
(1p21-p31, 3q25-qter, 8p21-pter, 9p21-pter, 9q21-q32, 11q21-q23,
and 13q32-q33) were correlated with chromosomal copy number
changes. As expected, chromosomal gains and losses were associated
with higher or lower expression of a subset of genes within the in-
volved chromosomal regions, respectively. The number of genes with
significant changes in gene expression in each band differed between
chromosomal regions. For example, among 50 genes in the chromo-
somal region 3q25-qter represented on the Lymphochip, 24 (48%)
were significantly overexpressed in patients with gains and amplifica-
tions, including PIK3CA, ACTL6A, YEATS2 (3q27), RFC4 (3q28),
and CENTB2 (3q29; Fig 2A). In contrast, in the chromosomal region
8p21-pter, only 27% of genes present on the Lymphochip showed
altered gene expression, with decreased levels as compared with MCL
patients with normal gene copy number of this genomic region (Fig
2B). In the 9q21-q32 region, 21 genes (48%) showed decreased ex-
pression in patients with chromosomal losses (Fig 2C) and, similarly,
62% of genes were affected by loss of genomic material in 13q32-q33
(Fig 2D), although the number of clones represented on the Lympho-
chip is relatively low. Regions 9p21-pter and 11q21-q23 were also
evaluated, with a percentage of 12.5% and 15% genes deregulated,
respectively (Appendix Fig A1, online only). Finally, no significantly
downregulated genes were found in the 1p21-p31 region. There were
no overexpressed genes in areas of CGH loss, nor were any genes
downregulated in regions with chromosomal gains in any of the re-
gions examined.
Prognostic Value of Chromosomal Alterations in MCL
The prognostic value of the global number of chromosomal
imbalances and specific altered regions with a frequency higher
than 10% was analyzed in the entire set of cyclin D1–positive
MCLs. The P values were adjusted for the step-up false discovery
rate.27 In the univariate analysis, an increased number of CGH
alterations (three or more v  three alterations per case) was
associated with shorter overall survival (OS; median OS, 1.6 v 5.1
year, respectively; HR, 2.08; 95% CI, 1.10 to 3.93; P  .019). In
addition, different chromosomal imbalances were associated with
poor OS in MCL patients, namely gains of 3q27-qter (median OS,
2 v 3.3 years; P  .039; HR, 2.27; 95% CI, 1.19 to 4.32), as well as
losses of 8p21-pter (median OS, 0.6 v 2.5 years; HR, 2.64; 95% CI,
1.21 to 5.75; P  .039;), 9p21-pter (median OS, 0.8 v 3.3 years; HR,
5.43; 95% CI, 2.44 to 12.0; P  .0001), and 9q21-q32 (median OS,
0.8 v 3.1 year; HR, 2.36; 95% CI, 1.23 to 4.52; P  .039). As
previously reported, patients with high proliferation signature







No. % No. %








Classic 58 82 6 100
Blastoid 13 18 —
Ann Arbor stage
I/II 8 11 —
III/IV 70 89 6 100
“B” symptoms 25 36 2 33
ECOG performance status
0-1 51 72 6 100
 2 12 17 —
LDH level  normal 26 37 2 33
BM involvement 39 57 6 100
IPI score
Low risk (0, 1) 16 26 —
Intermediate risk (2, 3) 35 56 6 100
High risk (4, 5) 11 18 —
Therapy
Combined chemotherapy 57 83 4 66
Combined chemotherapy plus
rituximab
9 13 1 17
No treatment 3 4 1 17
Response to therapy (CR  PR) 53 of 66 80 5 of 5 100
Median follow-up, months 23 34
Median survival, months 28 NR
Abbreviations: MCL, mantle cell lymphoma; ECOG, Eastern Cooperative
Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic
Index; BM, bone marrow; CR, complete response; PR, partial response; NR,
not reached.
No information on therapy was available for two patients.
Table 2. Commonly Altered Chromosomal Regions in Cyclin D1–Positive













3q21-qter 23 32 3 50
8q21-qter 8 11 2 33
15q21-qter 8 11 2 33
18q11-q23 8 11 —
Loss
1p21-p31 37 52 2 33
13q14-q34 29 41 4 67
11q21-q23 20 28 3 50
6q22-qter 16 22 —
6q15-q21 13 18 —
9p21-pter 13 18 2 33
9q21-qter 15 21 1(%) 17
8p21-pter 9 13 2 33
13q11-q13 12 17 2 33
17p13-pter 9 13 —
Abbreviation: MCL, mantle cell lymphoma.
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(median,  0.04) showed poorer OS than the remainder (me-
dian OS, 1.4 v 3.6 years, respectively; HR, 4.28; 95% CI, 2.21 to
8.30; P  .0001).
To determine whether the prognostic value of these chromo-
somal alterations was independent of proliferation, a multivariate
analysis was performed including the proliferation signature and all of
the CGH alterations with predictive value for OS. The multivariate
model showed that proliferation signature (HR, 4.25; 95% CI, 2.16 to
8.36; P  .0001), gain of 3q27-qter (HR, 2.51; 95% CI, 1.29 to 4.89;
P  .007), and loss of 9q21-q32 (HR, 2.48; 95% CI, 1.26 to 4.86;
P  .008) were associated simultaneously with poor OS. To visualize
the independent prognostic value of these two CGH alterations from
the proliferation signature, we subdivided the patients into four
groups according to their proliferation signature and the presence or
absence of the genetic alteration. Interestingly, the alterations in 3q27-
qter seem to provide prognostic information predominantly among
MCL patients with a low proliferation signature (Fig 3A), whereas
losses of 9q21-q32 may have higher impact in the MCL subgroup with
increased proliferation signature (Fig 3B).
DISCUSSION
MCL is a well characterized lymphoid neoplasm with the t(11;14)
(q13;q32) translocation as the primary genetic event leading to the
constant overexpression of cyclin D1.2 Recently, the gene expression
profile analysis of a large series of MCLs allowed us to identify a
particular subset of tumors with the same clinical presentation, mor-
phology, phenotype, and global expression profile as conventional
MCL except the lack of cyclin D1 expression and the t(11;14) translo-
cation.24,25 These tumors were termed cyclin D1–negative MCL. In-
terestingly, these patients overexpressed cyclin D2 or D3 suggesting
that upregulation of these G1 cyclins could be an alternative mecha-
nism in the pathogenesis of MCL. In this study, we demonstrate that
cyclin D1–negative MCL share the same secondary genomic alter-
ations as tumors overexpressing cyclin D1. The most frequent chro-
mosomal aberrations in MCL lacking cyclin D1 were gains of 3q, 8q,
and 15q, and losses of 1p, 8p23-pter, 9p21-pter, 11q21-q23, and 13q,
which are the same alterations most commonly observed in conven-
tional MCL. Most malignant lymphomas are characterized genetically
by a distinct recurrent primary chromosomal translocation such as the
t(11;14) in MCL, t(14;18) in follicular lymphoma, or the t(8;14) in
Burkitt’s lymphoma. In addition, the profile of secondary chromo-
somal alterations is also relatively specific for each disease entity. For
example, MCL and chronic lymphocytic leukemia (CLL) share some
common alterations such as losses of 13q and 11q, but isolated trisomy
12 is present almost exclusively in CLL, whereas gains of 3q and losses
of 1p are frequent in MCL but rare in CLL.28,29 In marginal zone
lymphoma, trisomy 3 is a common finding and, although in cyclin
D1–positive and cyclin D1–negative MCL gains of 3q are common,
trisomy 3 is not observed in our series. In addition, losses of 1p, 11q,
and 13q are not a feature of marginal zone lymphomas.30,31 Likewise,
the combination of secondary chromosomal alterations as demon-
strated in this study is not seen in follicular lymphomas that are mainly
characterized by gains of chromosome 7, 12, 18, and X, and losses of
6q.32 Therefore, the similar profile of secondary genetic alterations in
cyclin D1–positive and cyclin D1–negative tumors observed in our
study supports the idea that they correspond to the same biologic
entity and share similar genetic pathways of evolution.
The analysis of CGH and expression profile performed in DNA
and RNA obtained from the same tissue sample has allowed us to
study the relationship between genomic imbalances in MCL and the
expression of genes located within altered chromosomal regions, and
to identify potentially deregulated target genes. Recent studies in a
variety of tumors, among them diffuse large B-cell lymphoma
(DLBCL), have demonstrated a correlation between gene copy num-
ber changes and the expression level of genes encoded in numerically
altered genomic regions.26,33-37 In our study, we have examined the
relationship between chromosomal imbalances and the expression of
genes located in seven commonly altered chromosomal regions, some
of them also related to the proliferation of the tumors or the survival of
the patients (1p21-p31, 3q25-qter, 8p21-pter, 9p21-pter, 9q21-q32,
11q21-q23, and 13q32-q33). Concordant with our previous findings
in DLBCL, between 27% and 62% of genes located within these altered
chromosomal regions showed a significant change in expression level
in cases with chromosomal alterations. The finding that only a subset
of genes shows altered expression levels in chromosomal regions with
a genomic gain or loss is well in accordance with published literature in
A
B
1 2 3 4 5 X
6 7 8 9 10 11 12
181716151413
21 3
6 7 8 9 10 11 12
13 14 15 16 17 18
4 5 X
Fig 1. Ideogram of the distribution of gains and losses of genetic material
detected by comparative genomic hybridization in (A) cyclin D1–positive mantle
cell lymphoma (MCL) and (B) cyclin D1–negative MCL. Red bars on the left side
correspond to genetic losses; green bars on the right side indicate genetic gains.
Bold bars indicate amplifications.
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other types of lymphomas and in solid cancers.33,36 This may be, at
least in part, explained by the fact that only a subset of the genome is
expressed in the normal counterpart from which the malignant tumor
cell is derived. In addition, other genetic alterations or transcrip-
tional deregulation of key regulators in the tumor cell may influence
expression levels of genes located in chromosomal regions with
genomic imbalances that are independent of underlying DNA copy
number alterations. Interestingly, a substantial number of these dereg-
ulated genes were related to pathways that may influence the biology
of the tumor. Thus, a number of deregulated genes were involved in
cell proliferation, such as YEATS2, PICK3, ACTL6 (3q27), RFC4
(3q28), and CENTB2 (3q29); DNA repair and maintenance of chro-
mosome stability, such as FANCC and XPA (9q22), RAD23 (9q32),
ESCO2 (8p21), ATM (11q23), ERCC5, and LIG4 (13q33); or cel-
lular homeostasis and apoptosis, such as BIRC2 (11q22), SIAH2
(3q25), CASP1 and CASP4 (11q21), CLU and TNFRSF10D (8p21),
and PAK2 (3q29).
Gains and amplifications of the chromosomal region 3q25-qter
are a common feature of MCL, but also of the activated B-cell–like
subtype of DLBCL, as demonstrated in our previous analysis of
DLBCL.26 However, the particular group of genes deregulated by this
chromosomal aberration differs in part in the two types of lympho-
mas. Thus, 29 genes mapped to this region included in the Lympho-
chip microarray could be evaluated in both types of lymphomas. MCL
and activated B-cell–like DLBCL with gains in 3q25-qter had a signif-
icant upregulation of 16 (61%) and 10 (34%) of these genes, respec-
tively. Interestingly, seven genes (SIAH2, PDCD10, RFC4, OPA1,
PPP1R2, PAK2, and KIAA0226) were upregulated in both lymphoma
entities, whereas ten (GPR160, PH3, PIK3CA, FXR1, SIAT1, LPP,
CCDC50, CENTB2, ACK1, and TFRC) and three genes (GMPS,
TNSF10, and BDH) were differentially overexpressed only in MCL
and activated B-cell–like DLBCL, respectively. These findings suggest
that similar chromosomal aberrations in different lymphoma entities
may influence the expression of different subsets of genes.
MCL has an aggressive clinical course with a median survival of 3
to 4 years.38 However, clinical studies have recognized that some
patients have MCL with a more indolent behavior and have longer
survival, whereas others follow a very rapid course and die from the
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Fig 2. Influence of chromosomal alterations on locus-specific gene expression levels. (A) 3q, (B) 8p, (C) 9q, and (D) 13q. Genes are ordered according to their
chromosomal position (Genes On Sequence Map, Homo sapiens built 33). For genes with more than one microarray element on the Lymphochip, the average
expression from different clones was calculated. Genes with significant differences (P  .05) are highlighted in red. Amp, amplification.
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disease in less than 1 year.25,38 Clinical studies have identified several
prognostic factors including the International Prognostic Index.1,39-41
Molecular investigations have identified inactivation of p53, INK4a-
ARF locus, and high cyclin D1 expression levels as markers of shorter
survival.21,25,42 Recently, the proliferative activity has been recognized
as a powerful prognostic indicator that probably integrates multiple
oncogenic events in the progression of the tumors. The quantification
of the expression levels of 20 proliferation-related genes stratified
MCL patients with a difference of almost 6 years in the median surviv-
al.25 Conversely, previous genetic studies in MCL observed that gains
of chromosome 3q and losses of 8p, 9p, 9q, 13q, and 17p identify
patients with a more aggressive clinical evolution.7,11,23 However, the
relationship between genetic alterations and proliferation as prognos-
tic parameters is not known.
In our study, increased number of chromosomal alterations,
gains of 3q27-qter, and losses of 8p21-pter, 9p21-pter, and 9q21-q32
were associated with a poor clinical outcome. Interestingly, the prog-
nostic value of 3q27-qter gains and losses of 9q21-q32 were found to
be independent of the gene expression–based proliferation signature.
The finding that losses of 9p21-pter do not provide prognostic infor-
mation to the gene expression–based proliferation signature is ex-
pected given the strong association between losses of p16INK4a (located
at 9p21) and the proliferation of the tumor cells. It is an interesting
observation that chromosomal alterations in 3q27-qter and 9q21-q32
seem to influence the evolution of different subsets of tumors. Thus,
gains of 3q had a prognostic impact mainly in patients with low
proliferation, whereas losses of 9q improved the predictive value in the
subgroup of MCL with high proliferation. Therefore, the integration
of genetic information (3q and 9q alterations) and the quantitative
measurement of tumor cell proliferation (proliferation signature)
may improve the ability to predict survival in patients with MCL.
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Fig 3. Impact of genomic imbalances on survival of mantle cell lymphoma (MCL)
patients. Kaplan-Meier survival estimates of MCL patients (A) with genomic gains
of 3q27-qter (P  .039) and (B) losses of 9q22-q32 (P  .039) in comparison with
their stratification into two survival groups based on the gene expression–based
proliferation predictor model alone. n, number of patients; D, dead patients.
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